

Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

NCT05674994

Status	RECRUITING
Phase	Phase 3
Sponsor	Fondation Hôpital Saint-Joseph
Enrollment	110 participants

Key Eligibility Criteria

Inclusion (14)

- Patient is e 18 years of age
 - IPF or IPF (likely) diagnosis defined on 2018 international recommendations
 - Definite or suspected Acute Exacerbation defined by the international working group criteria after exclusion of alternative diagnoses of acute worsening
 - *The criteria of IPF-AE are as follows:
 - Previous or concurrent diagnosis of IPF (a)
- ... and 9 more (see full listing online)

Exclusion (12)

- Identified etiology for acute worsening (i.e.: infectious disease)
 - Known hypersensitivity to glucocorticoids or to any component of the study treatment
 - Patient requiring mechanical ventilation or already on mechanical ventilation
 - Active bacterial, viral, fungal or parasitic infection. On swab collected, only positive for SARS-CoV-2, Influenzae A, Influenzae B and Respiratory Syncytial Virus (RSV) result, are considered active viral infection. The others viruses (i.e. Rhinovirus, Adenovirus...) are not considered to be responsible of pneumonia.
 - Active cancer
- ... and 7 more (see full listing online)

Locations (29 total)

CHU ANgers, Angers, France
CHU de Besançon, Besançon, France
Hôpital Avicenne, Bobigny, France
... and 26 more locations

<https://clinicaltrials.gov/study/NCT05674994>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).